| Resumen: |
Background: Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of the current study was to assess the safety and effectiveness of both in an elderly real-life population. Methods: A multicentric retrospective study was performed on IBD patients who started vedolizumab or ustekinumab between 2010 and 2020. Clinical and endoscopic remission rates and (serious) adverse events (AE) were assessed. Results: A total of 911 IBD patients were included, with 171 (19%) aged above 60 (111 VDZ, 60 UST). Elderly patients treated with vedolizumab or ustekinumab had an increased risk for non-IBD hospitalization (10. 5% vs. 5. 7%, p = 0. 021) and malignancy (2. 3% vs. 0. 5%, p = 0. 045) compared to the younger population. Corticosteroid-free clinical (50% vs. 44%; p = 0. 201) and endoscopic remission rates (47. 9% vs. 31%, p = 0. 07) at 1 year were similar. Comparing vedolizumab to ustekinumab in the elderly population, corticosteroid-free (47. 9% vs. 31%, p = 0. 061) and endoscopic remission rates (66. 7% vs. 64. 4%, p = 0. 981) were similar. Vedolizumab- and ustekinumab-treated patients had comparable infection rates (13. 5% vs. 10. 0%, p = 0. 504), IBD flare-ups (4. 5% vs. 5%, p = 1. 000), the occurrence of new EIMs (13. 5% vs. 10%, p = 0. 504), a risk of intestinal surgery (5. 4% vs. 6. 7%, p = 0. 742), malignancy (1. 8% vs. 3. 3%, p = 0. 613), hospitalization (9. 9% vs. 11. 7%, p = 0. 721), and mortality (0. 9% vs. 1. 7%, p = 1. 000). AE risk was associated only with corticosteroid use. Conclusions: Ustekinumab and vedolizumab show comparable effectiveness and safety in the elderly IBD population. Elderly IBD patients have an increased risk for non-IBD hospitalizations and malignancy compared to the younger IBD population, with corticosteroid use as the main risk factor. |
visitante ::
identificación
(Ghent University)
